✦ LIBER ✦

Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C—A Reappraisal from a Tertiary Care Center in Northern India

✍ Scribed by Dixit, Vinod K.; Ghosh, Jayanta K.; Lamtha, Sangey C.; Kaushik, Pankaj; Goyal, Sundeep K.; Behera, Manas K.; Singh, Neha; Jain, Ashok K.

Book ID: 125817040
Publisher: Elsevier
Year: 2014
Tongue: English
Weight: 215 KB
Volume: 4
Category: Article
ISSN: 0973-6883
DOI: 10.1016/j.jceh.2014.05.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and tolerability of pegylated i

Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C – A report from a tertiary care center in northern India

✍ Ghosh, Jayant Kumar; Lamtha, Sangey Chopel; Kaushik, Pankaj; Goyal, Sundeep K.; 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 62 KB

Clinical and epidemiological profile of

Clinical and epidemiological profile of patients with chronic hepatitis c in a tertiary care hospital in northern India

✍ Ghosh, Jayant Kumar; Lamtha, Sangey Chopel; Kaushik, Pankaj; Goyal, Sundeep K.; 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 63 KB

A randomized controlled trial of pegylat

A randomized controlled trial of pegylated interferon α-2a (40 KD) or interferon α-2a plus ribavirin and amantadine vs interferon α-2a and ribavirin in treatment-naïve patients with chronic hepatitis C

✍ A. Mangia; G. L. Ricci; M. Persico; N. Minerva; V. Carretta; D. Bacca; M. Cela; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

Neutralizing antibodies to interferon-α

Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy*)

✍ Philippe Halfon; Sophie Pérusat; Marc Bourlière; Jean-Pierre Bronowicki; Pascale 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

## Abstract A lack of antiviral response in patients with chronic hepatitis C treated with pegylated (PEG)‐interferon (IFN)‐α‐2a + ribavirin (RIBA) may be explained by neutralizing antibodies to IFN‐α‐2a. The aim of this study was to assess neutralizing antibodies to IFN‐α‐2a and IFN levels in non‐

Prolonged treatment with pegylated inter

Prolonged treatment with pegylated interferon α 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan

✍ Sumio Watanabe; Nobuyuki Enomoto; Kazuhiko Koike; Namiki Izumi; Hajime Takikawa; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

Randomized trial comparing pegylated int

Randomized trial comparing pegylated interferon α-2b versus pegylated interferon α-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

✍ Montserrat Laguno; Carmen Cifuentes; Javier Murillas; Sergio Veloso; Maria Larro 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 370 KB